U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Earliest Event Reported: ~~May~~December 3128, ~~2019~~2020

Commission file number: 333-206839

HEALTH-RIGHT DISCOVERIES, INC.

(Exact name of registrant as specified in its charter)

Florida	45-3588650
(State or Other Jurisdiction of	(I.R.S. Employer
Incorporation or Organization)	Identification No.)

18851 NE 29th Avenue, Suite 700, Aventura, Florida 33180

(Address of Principal Executive Offices)

(305) 705-3247

(Registrant’s telephone number, including area code)

(Former name or address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions below:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240-14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Unless the context otherwise requires, all references in this Current Report on Form 8-K to “HRD,” “Health-Right,” “the Company,” “we,” “our” and “us” refers to Health-Right Discoveries, Inc. and its subsidiaries.

Item 58.0201 ~~Departure~~Other ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Information.

In ~~consideration~~September ~~for David Hopkins~~2017, ~~the~~HRD ~~Company’s~~purchased ~~Chief~~Common ~~Executive Officer and President~~Compounds, ~~assuming the additional duties of President of the Company’s two subsidiaries~~Inc., n/k/a CCI Billing, Inc. d/b/a ~~complete~~Complete Claim Management (“CCI”) and EZPharmaRx, LLC n/k/a Script Connection, LLC (~~collectively,~~“SCLLC”) from Hunter Burroughs (the “~~Subsidiaries~~Seller”). In August 2018, onthe ~~May~~Seller ~~31,~~filed ~~2019,~~a lawsuit against the Company ~~entered~~in ~~into~~the anCircuit ~~amended~~Court in and ~~restated~~for ~~employment agreement~~Miami-Dade ~~with~~County, MrFlorida. ~~Hopkins~~In the complaint, ~~effective~~the asSeller alleged breach of ~~April~~contract 15and fraud, ~~2019~~claiming (that the ~~“Effective~~Company ~~Date”),~~failed ~~which~~to ~~superseded~~pay ~~the~~him ~~January~~approximately $381,000 ~~2018~~in ~~employment~~excess ~~agreement~~working ~~between~~capital as of the ~~Company~~closing of the acquisition and ~~Mr.~~failed ~~Hopkins~~to reimburse him for certain credit card expenses. The Company ~~amended~~believed ~~and~~that ~~restated~~the ~~employment~~Seller’s ~~agreement~~claims iswere ~~for~~without anmerit ~~initial term~~because, among other things, his calculation of ~~three~~working ~~(3)~~capital did ~~years~~not ~~from~~follow the ~~Effective~~methodology ~~Date~~provided ~~and~~for ~~automatically~~in ~~renews~~the ~~for~~Securities ~~additional~~Purchase ~~three~~Agreement ~~(3)~~for ~~year~~the ~~periods~~transaction. In fact, ~~provided~~there ~~that~~was a working ~~the~~capital ~~Subsidiaries~~shortfall ~~achieve~~at ~~combined~~closing ~~Adjusted~~of ~~EBITDA~~approximately $725,000 (asfor ~~determined~~which bywe demanded payment in June 2018). We answered the ~~Company~~complaint, denying the Seller’s ~~accountants~~claims ~~from~~and filed a counterclaim against the ~~Subsidiaries’ financial~~Seller ~~statements~~for ~~used~~the insums ~~preparing~~due the Company for the working capital shortfall and for damages arising from Seller’s ~~audited~~breach ~~financial~~of ~~statements)~~contract, breach of ~~$3,000,000~~the ~~for~~covenant ~~any~~of ~~calendar~~good ~~year~~faith ~~during~~and fair dealing, fraud in the ~~initial~~inducement, ~~term~~indemnification, and ~~any~~violation ~~renewal~~of ~~term~~his non-competition and non-solicitation agreement with the Company.

~~The~~During ~~amended~~the ~~and~~discovery ~~restated employment agreement provides for an initial base salary of $250~~process,~~000.~~ In the ~~event~~Seller inproduced ~~any~~documents ~~calendar~~in ~~year~~response ~~during~~ to the ~~initial~~Company’s ~~term~~requests orfor ~~any~~production, ~~renewal~~responded ~~term~~to interrogatories, ~~the~~and ~~Subsidiaries~~sat ~~achieve~~for ~~combined~~two ~~Adjusted~~depositions. ~~EBITDA~~The ~~(as~~Company ~~determined~~discovered bythat the ~~Company’s accountants~~Seller ~~from~~perpetrated ~~the~~a ~~Subsidiaries’~~fraud ~~financial~~upon ~~statements~~the ~~used~~court inand ~~preparing~~ the Company’s ~~audited~~by, ~~financial~~among ~~statements) of~~other $3things,~~000,000,~~ ~~Mr.~~doctoring ~~Hopkins’~~several ~~annual~~critical ~~base~~emails, ~~salary~~providing ~~shall~~false ~~automatically~~responses ~~increase~~ to ~~$300~~sworn interrogatories,~~000~~ and ingiving false ~~the~~deposition ~~event~~testimony. inAt ~~any calendar year during~~ the ~~initial~~Seller’s ~~term~~second ordeposition, ~~any~~Health-Right’s ~~renewal~~counsel ~~term,~~confronted the ~~Subsidiaries~~Seller ~~achieve~~about the ~~combined~~discovery ~~Adjusted~~violations. ~~EBITDA~~In ~~(as~~response, ~~determined by~~ the ~~Company’s accountants~~Seller ~~from~~invoked ~~the~~his ~~Subsidiaries’~~Fifth ~~financial~~Amendment ~~statements~~privilege ~~used~~against inself-incrimination, ~~preparing~~and the ~~Company~~Seller’s counsel ~~audited~~subsequently ~~financial~~withdrew ~~statements) of~~from ~~$3,500,000,~~representing ~~his~~the ~~annual~~Seller. ~~base~~The ~~salary~~Company ~~shall~~promptly ~~automatically~~filed ~~increase~~a motion to ~~$350,000.~~strike ~~Mr.~~the ~~Hopkins~~Seller’s ~~will~~pleadings and ~~also~~for ~~receive~~the aentry ~~$600~~of ~~per~~a ~~month car~~default ~~allowance~~judgment ~~while~~against the ~~amended~~Seller ~~and~~for ~~restated~~his ~~employment~~fraud ~~agreement~~upon isthe ~~in effect~~court.

On December 28, 2020, the court granted HRD’s motion. The court found that the Seller had intentionally perpetrated a fraud ~~amended~~upon the court and ~~restated~~the ~~employment~~Company ~~agreement~~by ~~also~~doctoring ~~contains~~evidence, ~~customary~~withholding ~~confidentiality~~evidence, ~~non-competition~~destroying evidence, providing false interrogatory responses, and ~~change~~providing false deposition testimony. The court further found the Seller’s fraud was pervasive and permeated the entire case. As a result, the court struck the Seller’s pleadings in ~~control~~their ~~provisions~~entirety. Specifically, the court struck the Seller’s complaint and held that he would take nothing on his claims against the Company. The court also struck the Seller’s pleadings directed at the Company’s counterclaim and entered a final default judgment on liability against the Seller. The parties are currently in the process of setting a trial on damages.

The above summary of the amended and restated employment agreement is qualified in its entirety by reference to the copy of the amended and restated employment agreement filed as Exhibit 10.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
10.1		Amended and Restated Employment Agreement with David Hopkins

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	HEALTH-RIGHT DISCOVERIES, INC.
Dated: June 3, 2019	By:	/s/ David Hopkins
Dated: January 26, 2021	By:	/s/ David Hopkins
		David Hopkins, Chief Executive Officer and President
		(Principal Executive, Financial and Accounting Officer)

Filing Compare · Health-Right Discoveries, Inc.